ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Gregory D. Perry, Executive Vice President and Chief Financial Officer, has provided notice of his intention to resign from the Company to pursue other interests. His resignation is effective September 13, 2013.
Help employers find you! Check out all the jobs and post your resume.
